Applicant: Kouji Matsushima et al. Attorney's Docket No.: 14875-0157US1 / C1-A0308P-US

Serial No.: 10/574,045

Filed: February 21, 2007

Page : 2 of 6

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-5. (Canceled)

6. (Withdrawn) A method for producing the polypeptide of claim 31, the method comprising:

providing a host cell transformed with a DNA encoding the polypeptide; culturing the host cell, and collecting the polypeptide from the host cell or a culture supernatant thereof.

- 7. (Canceled)
- 8. (Withdrawn) A method for identifying a potential ligand for the polypeptide of claim 31, the method comprising:
- (a) contacting a candidate compound with the polypeptide or a cell expressing the polypeptide; and
- (b) determining whether the candidate compound binds to the polypeptide or cell, wherein binding to the polypeptide or cell is an indication that the candidate compound is a potential ligand for the polypeptide.
- 9. (Withdrawn) A method for identifying a potential agonist for the polypeptide of claim 31, wherein the method comprises:
 - (a) contacting a candidate compound with a cell expressing the polypeptide; and

Applicant: Kouji Matsushima et al. Attorney's Docket No.: 14875-0157US1 / C1-A0308P-US

Serial No.: 10/574,045

Filed: February 21, 2007

Page : 3 of 6

(b) determining whether the candidate compound induces the polypeptide to generate an ITIM signal activity, wherein the activity is an indication that the candidate compound is a potential agonist for the polypeptide.

- 10. (Withdrawn) A method for identifying a potential antagonist for the polypeptide of claim 31, wherein the method comprises:
 - (a) contacting a candidate compound with a cell expressing the polypeptide; and
- (b) determining whether an ITIM signal activity is reduced as compared with the activity in the absence of the candidate compound, wherein a reduction in activity is an indication that the candidate compound is a potential antagonist for the polypeptide.

11-30. (Canceled)

- 31. (Currently amended) An isolated polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 2, 4, and 6 SEQ ID NO: 2 or SEQ ID NO: 6, or the amino acid sequence encoded by SEQ ID NO: 3, beginning at nucleotide 88.
- 32. (Withdrawn) The polypeptide of claim 31, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2.
- 33. (Withdrawn) The polypeptide of claim 31, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 2.
- 34. (Currently amended) The polypeptide of claim 31, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 4 encoded by SEQ ID NO: 3, beginning at nucleotide 88.
- 35. (Currently amended) The polypeptide of claim 31, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 4 encoded by SEQ ID NO: 3, beginning at nucleotide 88.

Applicant: Kouji Matsushima et al. Attorney's Docket No.: 14875-0157US1 / C1-A0308P-US

Serial No.: 10/574,045

Filed: February 21, 2007

Page : 4 of 6

36. (Withdrawn) The polypeptide of claim 31, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 6.

37. (Withdrawn) The polypeptide of claim 31, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 6.

38-48. (Canceled)